Treatment of gastric cancer for survival-strategies in the USA and Japan

Lisa Baddi; Mary Mulcahy; Al Benson

doi:10.4993/acrt1992.11.15

Treatment of gastric cancer for survival-strategies in the USA and Japan

Lisa Baddi, Mary Mulcahy, Al Benson^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

Abstract

Chemotherapy has been shown to benefit patients with gastric cancer. The most effective regimen remains controversial. A recent large randomized clinical trial has demonstrated an advantage with the addition of docetaxel to 5-fluorouracil and cisplatin. New agents are being incorporated into the treatment of gastric cancer to maximize efficacy with minimal additional toxicity. Future clinical trials will explore the use of new agents as well as genetic polymorphisms that may influence drug metabolism and efficacy.

Original language	English (US)
Pages (from-to)	15-30
Number of pages	16
Journal	Annals of Cancer Research and Therapy
Volume	11
Issue number	1-2
DOIs	https://doi.org/10.4993/acrt1992.11.15
State	Published - 2003

Keywords

5-FU
Adenocarcinoma
Bryostatin
Cis-platin
Docetaxel
Drug toxicity
G17DT
Gastric cancer
Irinotecan
LV5FU2
Marimastat
Phase II and III trials
Survival
V325

ASJC Scopus subject areas

Oncology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4993/acrt1992.11.15

Cite this

@article{35984c483b684a6598ea24f52e657819,

title = "Treatment of gastric cancer for survival-strategies in the USA and Japan",

abstract = "Chemotherapy has been shown to benefit patients with gastric cancer. The most effective regimen remains controversial. A recent large randomized clinical trial has demonstrated an advantage with the addition of docetaxel to 5-fluorouracil and cisplatin. New agents are being incorporated into the treatment of gastric cancer to maximize efficacy with minimal additional toxicity. Future clinical trials will explore the use of new agents as well as genetic polymorphisms that may influence drug metabolism and efficacy.",

keywords = "5-FU, Adenocarcinoma, Bryostatin, Cis-platin, Docetaxel, Drug toxicity, G17DT, Gastric cancer, Irinotecan, LV5FU2, Marimastat, Phase II and III trials, Survival, V325",

author = "Lisa Baddi and Mary Mulcahy and Al Benson",

year = "2003",

doi = "10.4993/acrt1992.11.15",

language = "English (US)",

volume = "11",

pages = "15--30",

journal = "Annals of Cancer Research and Therapy",

issn = "1344-6835",

publisher = "PJD Publications Ltd",

number = "1-2",

}

TY - JOUR

T1 - Treatment of gastric cancer for survival-strategies in the USA and Japan

AU - Baddi, Lisa

AU - Mulcahy, Mary

AU - Benson, Al

PY - 2003

Y1 - 2003

N2 - Chemotherapy has been shown to benefit patients with gastric cancer. The most effective regimen remains controversial. A recent large randomized clinical trial has demonstrated an advantage with the addition of docetaxel to 5-fluorouracil and cisplatin. New agents are being incorporated into the treatment of gastric cancer to maximize efficacy with minimal additional toxicity. Future clinical trials will explore the use of new agents as well as genetic polymorphisms that may influence drug metabolism and efficacy.

AB - Chemotherapy has been shown to benefit patients with gastric cancer. The most effective regimen remains controversial. A recent large randomized clinical trial has demonstrated an advantage with the addition of docetaxel to 5-fluorouracil and cisplatin. New agents are being incorporated into the treatment of gastric cancer to maximize efficacy with minimal additional toxicity. Future clinical trials will explore the use of new agents as well as genetic polymorphisms that may influence drug metabolism and efficacy.

KW - 5-FU

KW - Adenocarcinoma

KW - Bryostatin

KW - Cis-platin

KW - Docetaxel

KW - Drug toxicity

KW - G17DT

KW - Gastric cancer

KW - Irinotecan

KW - LV5FU2

KW - Marimastat

KW - Phase II and III trials

KW - Survival

KW - V325

UR - http://www.scopus.com/inward/record.url?scp=5044224209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5044224209&partnerID=8YFLogxK

U2 - 10.4993/acrt1992.11.15

DO - 10.4993/acrt1992.11.15

M3 - Article

AN - SCOPUS:5044224209

SN - 1344-6835

VL - 11

SP - 15

EP - 30

JO - Annals of Cancer Research and Therapy

JF - Annals of Cancer Research and Therapy

IS - 1-2

ER -

Treatment of gastric cancer for survival-strategies in the USA and Japan

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this